China National Accord Medicines Corporation Ltd. announced unaudited earnings results for the six months ended June 30, 2017. For the six months, the company announced operating income was RMB 20,524,807,669.57 compared to RMB 20,562,402,047.82 for the same period a year ago. Net profit attributable to shareholders of the company was RMB 556,125,318.19 compared to RMB 659,078,223.36 for the same period a year ago. Net profit attributable to shareholders of the company after deducting non-recurring gains and losses was RMB 546,253,390.00 compared to RMB 401,762,449.20 for the same period a year ago. Net cash flow arising from operating activities was RMB 228,337,431.40 compared to RMB 829,582,933.34 for the same period a year ago. Basic and diluted earnings per share were RMB 1.299 compared to RMB 1.558 for the same period a year ago. Weighted average ROE was 6.41% compared to 8.59% for the same period a year ago.